Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Free Cash Flow: 2021-2025

Historic Free Cash Flow for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $33.1 million.

  • Kiniksa Pharmaceuticals International's Free Cash Flow rose 1564.36% to $33.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.8 million, marking a year-over-year increase of 827.00%. This contributed to the annual value of $25.4 million for FY2024, which is 92.94% up from last year.
  • Kiniksa Pharmaceuticals International's Free Cash Flow amounted to $33.1 million in Q3 2025, which was up 18.77% from $27.9 million recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Free Cash Flow ranged from a high of $62.0 million in Q3 2022 and a low of -$40.2 million during Q1 2021.
  • Over the past 3 years, Kiniksa Pharmaceuticals International's median Free Cash Flow value was $5.1 million (recorded in 2024), while the average stood at $11.1 million.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Free Cash Flow slumped by 113.31% in 2024, and later skyrocketed by 1,564.36% in 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Free Cash Flow (Quarterly) stood at -$19.1 million in 2021, then surged by 39.67% to -$11.5 million in 2022, then spiked by 136.98% to $4.3 million in 2023, then soared by 337.90% to $18.7 million in 2024, then skyrocketed by 1,564.36% to $33.1 million in 2025.
  • Its Free Cash Flow stands at $33.1 million for Q3 2025, versus $27.9 million for Q2 2025 and $22.2 million for Q1 2025.